Health
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiationEton has integrated full Eton Cares patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programsHEMANGEOL is the only FDA-approved treatment for infantile hemangioma, a pediatric rare disease that can be time-sensitive DEER PARK, Ill., May 01, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nas
About this update from Eton Pharmaceuticals, Inc.
[{"type":"image","alt":"Eton Pharmaceuticals","displaySize":"","headline":null,"caption":"Eton Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/28f8553e49220b3671789b0841a3f340"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wcuthC_koftYVXvofM_o3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/28f8553e49220b3671789b0841a3f340","width":300,"height":86}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiation","length":115,"tagName":"p"}]},{"val":[{"type":"text","content":"Eton has integrated full Eton Cares patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programs","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"HEMANGEOL is the only FDA-approved treatment for infantile hemangioma, a pediatric rare disease that can be time-sensitive","length":122,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":393,"olType":false},{"type":"text","content":"DEER PARK, Ill., May 01, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the relaunch of HEMANGEOL®.","length":270,"tagName":"p"},{"type":"text","content":"“We are excited to deliver another major product launch for the company. HEMANGEOL is a critical and time-sensitive therapy where early treatment can meaningfully impact outcomes, and the only FDA-approved treatment for infantile hemangiomas. With the integration of Eton Cares and a dedicated rare disease specialty pharmacy model, we are focused on helping patients start therapy quickly and ensuring families are supported from prescription through treatment. Our HEMANGEOL commercial team has been actively working with caregivers, healthcare professionals, and pharmacies to ensure a seamless transition for patients,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.","length":674,"tagName":"p"},{"type":"text","content":"“Infantile hemangiomas can evolve rapidly, and timely intervention is critical. In practice, the challenge is of...